CSJ Stock Overview Researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for CSL Historical stock prices Current Share Price AU$170.10 52 Week High AU$192.00 52 Week Low AU$160.66 Beta 0.31 1 Month Change 1.15% 3 Month Change -5.11% 1 Year Change -3.57% 3 Year Change -3.71% 5 Year Change -8.65% Change since IPO 6,359.56%
Recent News & Updates
CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE) Dec 14
CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy Oct 17
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain Sep 14
Now 20% undervalued Sep 04
Upcoming dividend of US$1.45 per share Sep 02
Final dividend of US$1.45 announced Aug 15 See more updates
CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE) Dec 14
CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy Oct 17
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain Sep 14
Now 20% undervalued Sep 04
Upcoming dividend of US$1.45 per share Sep 02
Final dividend of US$1.45 announced Aug 15
Full year 2024 earnings released: EPS: US$5.47 (vs US$4.55 in FY 2023) Aug 13 CSL Limited to Report First Half, 2025 Results on Feb 11, 2025
Now 20% undervalued Jul 09
Now 22% undervalued Jul 01
Now 20% undervalued Jun 21
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine May 23
Now 22% undervalued after recent price drop May 18
CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy Apr 24
CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee Mar 06
Upcoming dividend of US$1.19 per share Mar 04
First half dividend of US$1.19 announced Feb 16
First half 2024 earnings released: EPS: US$3.94 (vs US$3.37 in 1H 2023) Feb 14 CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024
CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human) Feb 12
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster Dec 21
CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024 Dec 15
CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B Dec 12
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults Nov 29
Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B Oct 28
CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024 Oct 17 CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines
CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources Sep 20
Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19 Sep 06
Upcoming dividend of US$1.29 per share at 1.4% yield Sep 04
Independent Non-Executive Chairman recently sold €3.3m worth of stock Aug 26
CSL Appoints Jeffrey Ball as First Chief Sustainability Officer Aug 18 CSL Limited, Annual General Meeting, Oct 09, 2024
Full year 2023 earnings released: EPS: US$4.55 (vs US$4.81 in FY 2022) Aug 15
CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023 Aug 04
Now 21% undervalued after recent price drop Jul 26
Now 20% undervalued after recent price drop Jul 10
Upcoming dividend of US$1.07 per share at 1.1% yield Mar 02
First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022) Feb 14
CSL Limited Announces Interim Dividend, Payable on 5 April 2023 Feb 14
CSL Limited, Annual General Meeting, Oct 11, 2023 Jan 10
CSL Limited to Report First Half, 2023 Results on Feb 14, 2023 Jan 09
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases Jan 06 CSL Limited Announces Management Changes CSL Limited Announces Chief Executive Officer Changes
CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B Nov 23
Now 21% undervalued after recent price drop Nov 05
Independent Non-Executive Director recently bought €174k worth of stock Oct 27
CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates Oct 06
Non-Independent Non-Executive Director recently sold €4.3m worth of stock Sep 03
Upcoming dividend of US$1.18 per share Aug 30
Full year 2022 earnings released: EPS: US$4.81 (vs US$5.22 in FY 2021) Aug 18
CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE) Aug 18 CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022
Now 23% undervalued May 08
Upcoming dividend of US$1.04 per share Feb 28
Now 22% undervalued after recent price drop Feb 19
First half 2022 earnings: EPS in line with analyst expectations despite revenue beat Feb 17 CSL Limited Provides Earnings Guidance for the Fiscal Year 2022 CSL Limited has completed a Follow-on Equity Offering in the amount of AUD 750.028364 million. Feb 15
CSL Limited (ASX:CSL) entered into a definitive agreement to launch public tender offer to acquire Vifor Pharma AG (SWX:VIFN) from Patinex AG and other for CHF 10.9 billion. Dec 15
Vifor Pharma and CSL Confirm Merger Talks Dec 14 Vifor Says Regularly in Talks with Other Market Participants After Reports
Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine Nov 24
MD, CEO & Executive Director recently sold €2.9m worth of stock Nov 06
MD, CEO & Executive Director recently sold €3.0m worth of stock Sep 07
High number of new directors Sep 02
Upcoming dividend of US$1.18 per share Aug 26
Full year 2021 earnings released: EPS US$5.22 (vs US$4.63 in FY 2020) Aug 21
CSL Limited Provides Financial Guidance for Fiscal 2022 Aug 20
Independent Non-Executive Director Shah Hussain has left the company Jun 26
Seqirus Announces Health Canada Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older Mar 19
New 90-day low: €164 Mar 05
Independent Non-Executive Chairman recently bought €53k worth of stock Feb 28
First half 2021 earnings released: EPS US$3.98 (vs US$2.75 in 1H 2020) Feb 20
Revenue beats expectations Feb 20
CSL Limited to Report First Half, 2021 Results on Feb 18, 2021 Feb 10
Independent Non-Executive Director has left the company Feb 01
CSL Limited Announces Resignation of Pascal Soriot from the Position of Non-Executive Director, Effective 1 February 2021 Jan 28
New 90-day low: €172 Jan 14
New 90-day high: €189 Nov 11
CSL Limited Announces Management Changes Oct 01
MD, CEO & Executive Director recently sold €25.4m worth of stock Aug 30
New 90-day high - €189 Aug 20
Full year earnings released Aug 20 Shareholder Returns CSJ DE Biotechs DE Market 7D 2.0% 5.8% 2.0% 1Y -3.6% -6.1% 9.6%
See full shareholder returns
Return vs Market: CSJ underperformed the German Market which returned 9.1% over the past year.
Price Volatility Is CSJ's price volatile compared to industry and market? CSJ volatility CSJ Average Weekly Movement 2.7% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: CSJ has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: CSJ's weekly volatility (3%) has been stable over the past year.
About the Company CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Show more CSL Limited Fundamentals Summary How do CSL's earnings and revenue compare to its market cap? CSJ fundamental statistics Market cap €83.31b Earnings (TTM ) €2.55b Revenue (TTM ) €14.30b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CSJ income statement (TTM ) Revenue US$14.80b Cost of Revenue US$7.10b Gross Profit US$7.71b Other Expenses US$5.06b Earnings US$2.64b
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 10, 2025
Earnings per share (EPS) 5.46 Gross Margin 52.06% Net Profit Margin 17.85% Debt/Equity Ratio 54.2%
How did CSJ perform over the long term?
See historical performance and comparison Dividends
1.5% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/07 02:12 End of Day Share Price 2025/01/07 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources CSL Limited is covered by 29 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Russell Wright Barclay Pearce Capital Pty Limited Saul Hadassin Barrenjoey Markets Pty Limited Thomas Wakim Bell Potter
Show 26 more analysts 
